Clinical Trial Update: Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01) [NA]

View source ↗

Summary

This clinical trial update notes the completion of a study evaluating donor-derived EBV-specific T cells for Epstein-Barr virus-associated lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Associated Lymphoma

Drugs mentioned

• Donor-derived EBV-specific T cells (EBV-specific T cells)

Snippet

Sponsor: Ciusss de L'Est de l'Île de Montréal | Conditions: EBV Associated Lymphoma | NA | Status: COMPLETED